Avalo Therapeutics 2025 Q3 Earnings Net Loss Surges 323.5% as Revenue Collapses to Zero

Avalo Therapeutics (AVTX) reported fiscal 2025 Q3 results marked by a dramatic shift from profit to loss, with GAAP EPS of -$2.19 missing analyst estimates of -$1.66. The company’s cash runway remains intact through 2028, .

Revenue

, a stark decline from $249,000 in 2024 Q3. This collapse reflects the expiration of the Millipred® license and supply agreement in Q3 2023, leaving the company without product sales during the period.

Earnings/Net Income

Avalo Therapeutics swung to a loss of $2.19 per share in 2025 Q3 from a profit of $0.98 per share in 2024 Q3 (323.5% negative change). The company reported a net loss of $-30.63 million in 2025 Q3, a 232.9% deterioration from the net income of $23.04 million in 2024 Q3. The EPS and net loss reflect a dramatic deterioration, with a 323.5% negative change year-over-year.

Price Action

, has tumbled 14.50% during the most recent full trading week, and has jumped 14.39% month-to-date.

CEO Commentary

Dr. emphasized Avalo’s transition from enrollment to trial completion in the Phase 2 LOTUS trial of AVTX-009 for , stating the company is “fully focused” on preparing for mid-2026 topline data and Phase 3 planning. Leadership updates included appointing to the Board and Taylor Boyd as Chief Business Officer. The CEO highlighted $112 million in cash and short-term investments as of September 30, 2025, sufficient to fund operations into 2028.

Guidance

Avalo expects topline data from the Phase 2 LOTUS trial in mid-2026 and anticipates current cash, cash equivalents, , 2025) to fund operations into 2028. , .

Post-Earnings Price Action Review

The stock price of Avalo Therapeutics exhibited mixed performance following the earnings release. , . Analysts remain divided, with a “buy” consensus reflecting optimism about AVTX-009’s potential despite the company’s financial challenges.

Additional News

Avalo Therapeutics completed enrollment in its Phase 2 LOTUS trial for AVTX-009, with topline data expected mid-2026. The company appointed Kevin Lind to its Board of Directors and expanded leadership with Taylor Boyd as Chief Business Officer and as Senior Vice President of Human Resources. These moves underscore strategic investments in governance and operational execution. , as of September 30, 2025, , providing stability during its clinical development phase.

Guidance (Continued)

Forward-looking statements include reliance on trial timelines, regulatory outcomes, and market conditions, with risks detailed in SEC filings. , , attributed to warrant-related expenses and increased R&D spend.